Simtuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Simtuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target LOXL2
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6558H10134N1736O2037S50
Molar mass 147.5 kg/mol

Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.[1] It binds to LOXL2 and acts as an immunomodulator.[2] In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.[3]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab, American Medical Association.
  2. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2). 
  3. ^ http://www.gilead.com/news/press-releases/2016/1/gilead-terminates-phase-2-study-of-simtuzumab-in-patients-with-idiopathic-pulmonary-fibrosis